FolikoInvest
Posted - 18 hours ago
$ALNY Alnylam Pharmaceuticals is making waves with early-stage results for nucresiran, an RNAi therapeutic that shows over 90% reduction in serum TTR levels within 15 days. As the ATTR treatment market heats up, can Alnylam maintain its edge against emerging competitors? https://folikoinsights.com/article/ALNY/2024/11/20/alnylam-pharmaceuticals-reports-positive-early-stage-results-for-nucresiran-aiming-to-compete-in-att?cid=QeK2m1hv2Lwxcnng
BenicioMontgomery
Posted - 20 hours ago
$ALNY $BIIB LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
HayleyMason__
Posted - 1 day ago
🚨 STOCK ALERT: MYNZ 🚨 🔥 Frankie Muniz is ALL IN—Malcolm in the Middle star & NASCAR #33 driver is now repping MYNZ! 🔎 Petra (ex-Obama advisor) dropped hints about a major U.S. lab partnership—this could be game-changing. 📈 6 news hits in 3 weeks = strong momentum. Something BIG is building here. 🌍 Already solid in the EU market, expanding with insurance-covered tests—this isn’t just hype, it’s execution. 💡 Their test has 88% accuracy, crushing competitors: EXAS (42%) & GH (20%)—clear leader in diagnostics. 💰 $1.5M private placement secured = cash on hand to scale up. 🚀 CEO teasing big plans ahead—keep an eye on this leadership. 📊 New offering deal + TMO partnership = validation and growth catalysts. ⚡ MYNZ is ticking all the boxes for a breakout! Don’t let this one fly under your radar! 💥 $GSK $TAK $ALNY
NVDAMillionaire
Posted - 2 days ago
$ALNY Alnylam Pharmaceuticals, Inc. (ALNY): A Pioneer in RNAi Therapeutics Charting a Transformative Path https://beyondspx.com/article/alnylam-alny-a-promising-biotech-poised-for-transformative-growth
ntlaguy
Posted - 3 days ago
$ALNY and $NTLA Phase 1 Population Differences: • ALNY's Nucresiran: ◦ Phase 1 trial conducted in HEALTHY adults, which eliminates confounding factors related to disease severity but does not evaluate efficacy or safety in ATTR amyloidosis patients. ◦ Focused on understanding pharmacodynamics (PD) and pharmacokinetics (PK) without direct clinical implications for disease progression. • NTLA-2001: ◦ Evaluated directly in patients with ATTR amyloidosis (ATTR-CM and ATTRv-PN), providing disease-relevant efficacy data. ◦ Showed evidence of disease modification, with stabilization or improvement in clinical and cardiac biomarkers, including NT-proBNP and 6MWT.
Not saying ALNY's drug doesn't work, but they were treating healthy patients while NTLA was treating some of the worst ATTR patients and showed better results than anything else out there.
DonCorleone77
Posted - 3 days ago
$ALNY Alnylam Pharmaceuticals announces interim Phase 1 data of nucresiran Alnylam Pharmaceuticals announced the presentation of new results from its Phase 1 study of nucresiran, a next-generation RNAi therapeutic in development for the treatment of transthyretin amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These new results demonstrated that a single dose of nucresiran at 300 mg or higher led to rapid knockdown of serum TTR with low inter-patient variability, with mean reductions of greater than 90% from baseline achieved at Day 15 and sustained through at least Day 180. At these doses, peak reduction of mean TTR levels of greater than 96% were achieved by Day 29. Furthermore, serum TTR levels remained substantially reduced at Day 360 with a mean reduction of greater than 70% after a single 300 mg dose. Day 360 results are not yet available for the 600 mg and 900 mg dose cohorts. All doses of nucresiran have been well tolerated to date. The ongoing Phase 1 dose-finding study evaluated the safety, as well as pharmacodynamics and pharmacokinetics, of single doses of nucresiran in healthy subjects. As previously presented at Alnylam's R&D Day in December 2023, a single dose of nucresiran led to rapid knockdown of serum TTR that was highly durable. In subjects receiving a single 300 mg dose of nucresiran, mean serum TTR reduction of 90.3% was observed at Day 15, 96.5% at Day 29, and 92.6% at Day 180. At Day 360, mean serum TTR Reduction was 71.12%. In subjects receiving a single 600 mg dose, mean serum TTR reduction of 95.0% was observed at Day 15, 97.8% at Day 29, and 96.0% at Day 180. In subjects receiving a single 900 mg dose, mean serum TTR reduction of 91.7% was observed at Day 15, 96.7% at Day 29, and 94.2% at Day 180. As of the data cutoff date, TTR knockdown levels at Day 360 were not available for either the 600 mg or 900 mg cohort. There has been low inter-patient variability in the TTR reduction observed; at Day 29, TTR reduction ranged from 96.0 - 96.7% in the 300 mg cohort, 96.6 - 98.6% in the 600 mg cohort, and 96.0 - 97.3% in the 900 mg cohort. In the study, nucresiran has been well tolerated at all tested doses. The majority of adverse events across doses have been mild and none have been considered to be related to treatment. There have been no injection site reactions and no safety signals identified, including no liver-related signals.
ntlaguy
Posted - 3 days ago
Detailed comparison of NTLA-2001 and Alnylam's Nucresiran
1. Mechanism of Action: • NTLA-2001 $NTLA ◦ In vivo CRISPR-Cas9 gene editing directly modifies the TTR gene, providing a one-time, potentially permanent treatment. ◦ Aimed at halting disease progression by permanently reducing TTR production. • Nucresiran $ALNY ◦ RNAi-based therapy that silences the TTR gene to reduce TTR protein levels. ◦ Requires biannual or annual subcutaneous injections, making it a recurring treatment rather than a one-time solution.
Advantage: Intellia’s one-time CRISPR-based treatment may provide a superior patient experience and long-term cost-effectiveness compared to Alnylam's recurring treatment regimen.
2. Efficacy (TTR Knockdown): • NTLA-2001: ◦ Achieved 90% TTR reduction at 12 months, sustained for over 2 years without waning. ◦ Durability extends beyond current observation points with no additional dosing. • Nucresiran: ◦ Achieved 90%-96% TTR reduction at Day 15–29, sustained at >90% through 6 months, with a decline to ~70% at 12 months for the 300 mg dose. ◦ Higher doses (600 mg and 900 mg) maintained ~90% TTR knockdown at 6 months, with 12-month data pending.
Advantage: NTLA-2001 demonstrates more durable TTR knockdown with a single treatment, while Nucresiran's durability diminishes over time at lower doses.
3. Clinical Impact: • NTLA-2001: ◦ Demonstrated disease stabilization and improvement across multiple clinical measures (e.g., NT-proBNP, NYHA classification, 6MWT). ◦ Showed consistent benefits even in advanced ATTR-CM patients with heart failure. ◦ Improvement/stabilization observed in neuropathy scores (ATTRv-PN). • Nucresiran: ◦ Focused primarily on pharmacodynamic endpoints in healthy subjects, with future plans for Phase 3 in ATTR patients. ◦ Lacks clinical efficacy data (e.g., cardiac or neuropathy improvements).
Advantage: NTLA-2001 has proven clinical impact in ATTR patients, while Nucresiran is still early-stage without demonstrated clinical benefit in a patient population.
4. Safety Profile: • NTLA-2001: ◦ Generally well-tolerated; main adverse events were mild-to-moderate infusion-related reactions (IRRs). ◦ Long-term follow-up shows no safety signals or waning efficacy. • Nucresiran: ◦ Well-tolerated with no safety signals or injection site reactions observed in Phase 1. ◦ Longer-term safety data not yet available for higher dose cohorts.
Advantage: Both therapies appear safe, but NTLA-2001 has a longer safety follow-up period.
5. Commercial and Strategic Potential: • NTLA-2001: ◦ One-time treatment eliminates patient adherence challenges and may reduce long-term healthcare costs. ◦ Likely to command a high premium price due to the transformative nature of gene editing. • Nucresiran: ◦ Recurring dosing (biannual or annual) aligns with traditional pharma models, generating sustained revenue but posing challenges for patient compliance. ◦ May be seen as incremental improvement over Alnylam’s existing therapies (e.g., Onpattro and Amvuttra).
Advantage: NTLA-2001’s gene-editing approach positions it as a potential paradigm shift, while Nucresiran might be considered an evolutionary improvement.
6. Development Timelines: • NTLA-2001: Currently in Phase 1 with ongoing Phase 3 trials, positioning it closer to potential commercialization. • Nucresiran: Phase 1 data presented, with Phase 3 plans expected in Q1 2025.
Advantage: NTLA-2001 is farther along in clinical development, which could lead to earlier market entry.
Conclusion: Which is Better? • NTLA-2001 (Intellia): Likely the better option based on its one-time treatment, durability, proven clinical benefits, and potential to transform ATTR treatment. However, both therapies address significant unmet needs and could complement each other in the market.
LewisDaKat
Posted - 3 days ago
News $ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose https://marketwirenews.com/news-releases/alnylam-announces-interim-phase-1-data-of-nucresiran-5398603080386668.html $ALNY
zztopps
Posted - 5 days ago
$ALNY This is f'ing nuts! XBI bad, this is ridiculous. Down 60 points in a week.
valueforme
Posted - 6 days ago
$ALNY $NVS $CDXS I told ya - inclisiran
smartkarma
Posted - 1 week ago
$ALNY | Alnylam Pharmaceuticals: Pipeline Expansion In Neurodegenerative Diseases As A Pivotal Factor Driving Growth! - Major Drivers
"Alnylam Pharmaceuticals demonstrated strong financial and operational performance in its Q3 2024 results, marking a significant phase of growth..." - Baptista Research (Baptista Research)
Read more: https://www.smartkarma.com/insights/alnylam-pharmaceuticals-pipeline-expansion-in-neurodegenerative-diseases-as-a-pivotal-factor-driving-growth-major-drivers
Wrangler4
Posted - 1 week ago
$AGIO…..Hey Butt Boy Berens from Leerink….you are clearly not paying attention and panned AGIO for your own benefit to get in..Trump has Melania pushing cures, accelerated approvals for SCD as you sit and try to come up with a writers look into SCD. Your analysis is behind times, and more an English essay, than a Petrie Dish.
Listen and weep Beren’s Boy, your credibility is Done and Done ! Shall we add in your take on $ALNY , another missed opportunity by your institutional clients !!!
Others listen, and now she is in the White House , much like Hillary took on Healthcare for Bill. Even @mghmd has countered your pathetic role on SCD
Wrangler4
Posted - 1 week ago
$ALNY @TwittStoxx @NYNJlawyer @jjl013 …looked alny-ers !!! This buffoons comment , you are a POS , hahaha, with Blackrock as your finance arm , hahahaah
Wrangler4
Posted - 1 week ago
$SAVA @TwittStoxx @NYNJlawyer @jjl013 Haha $alny ..272 , your pos close to bankruptcy and they have an Alzheimer’s drug !!
DonCorleone77
Posted - 2 weeks ago
$AZN $KYMR $VIR $ALNY $IVVD U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says U.S. drugmakers and biotechs rely on Chinese partners for manufacturing, research, and ingredients, but, with geopolitical tensions rising, companies are now looking for alternatives, Jared Hopkins and Clarence Leong of The Wall Street Journal reports. Pharmaceutical and biotechnology companies of all side are saying it's time to reduce China risk. Industry officials, however, note one consequence of this move may be slower drug rollouts and higher costs in the U.S. Companies making this move include AstraZeneca (AZN), Kymera Therapeutics (KYMR), Amicus Therapeutics (FOLD), Vir Biotechnology (VIR), Alnylam Pharmaceuticals (ALNY), Invivyd (IVVD).
valueforme
Posted - 10/31/24
$CDXS By the way, after more thinking, the partner we might see on stage at Tides EU might also be Novartis. They have a long history of relationships with Codexis. And Leqvio (inclisiran) is $ALNY / $NVS partnered drug. And inclisiran is actually the first siRNA drug in a major indication - atherosclerotic cardiovascular disease (ASCVD) and the sales are ramping up pretty nicely - $198M in Q3 2024. It will definitelly become a blockbuster drug, so siRNA manufacturing scaling for inclisiran is a hot topic for Novartis (and Alnylam really)
Wrangler4
Posted - 10/31/24
$AGIO Loser Berens from Leerink ( out of receivership) covering Agio
Once again misses the boat..is math too hard for him, or has he been on sabbatical with writers block ? Raymond James, never in bankruptcy, called it before useless Berens Oh well explains all Leerink misses on agio and $ALNY
valueforme
Posted - 10/31/24
$CDXS Tides EU as well: "Showcase results from another collaboration with a top siRNA drug innovator " $ARWR or $ALNY ? Likely ALNY
IN0V8
Posted - 10/30/24
$ALNY Opportunity Jefferies raises target price to $328 from $315
Tumble51
Posted - 10/27/24
$AQST $SPRY Don’t bet on Leerink …they blew it at $ALNY and $AGIO
Tumble51
Posted - 10/24/24
$AGIO $ALNY Of course, a laid off Alexion middle manager ! Pulled by the strings of the little man syndrome ! Schenkien..better though than a deranged TRUMP, as Meadows was , lol
Dkll303
Posted - 10/23/24
$AGIO RED LIKE EVERY DAY ! Goff has no idea how to make value or the word Green He should take lessons from Green , yes, her, at $ALNY …lol But he would only fcuk up her suggestions.
frontiere
Posted - 10/23/24
$BBIO BridgeBio ref=$24.74 — small long now, since Aug have had to be nimble taking profit on small spikes and re-buying / selling puts on down moves. Quite a tug-of-war in this name between bulls and bears.
Coming up catalysts: 👍 PDUFA 2024-11-29 acoramidis in ATTR-CM — BMO sell-side put out a 🚩 note on 2024-09-24 suggesting AdCom — I lean dismissive of it, especially so close to PDUFA date.
🧐👍 Alnylam 2024-10-09 submitted sNDA to the FDA for vutrisiran, an investigational RNAi for ATTR amyloidosis with cardiomyopathy (ATTR-CM) , based on positive HELIOS-B Ph3 — by early Dec we MIGHT hear if FDA wants Adcom for it — 🚩for ALNY 🧐
Good high-level summary of 🐂 vs 🐻 from Piper Sandler analyst Biren Amin for BiotechTV Brad Loncar: https://www.biotechtv.com/post/biren-amin-october-22-2024#vimeo_chapter_1022283364=16177312
C.f. $ALNY $CYTK $NTLA $PFE
CDMO
Posted - 10/22/24
$ALNY monster
anachartanalyst
Posted - 4 weeks ago
$ALNY
https://anachart.com/wp-content/uploads/ana_temp/1729515704_soc-img.jpg
briefingcom
Posted - 1 month ago
$ALNY: Alnylam Pharma Canada signs letter of intent from pan-Canadian Pharmaceutical Alliance for the public reimbursement of AMVUTTRA for the treatment of hereditary transthyretin-mediated amyloidosis in adults https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241018082027ALNY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
biochirp
Posted - 1 month ago
$PRQR $ALNY would be silly not to bid for this IP estate
Tumble51
Posted - 1 month ago
$ALNY $KYMR $RYTM $CADL …yes the tts hit their premiums yesterday, without roll up and now, they play no more !!! Typical 3rd week of the month here Add $QURE to the list , lol. “ patent “ over “ truth “ ( ya right , left with your draws down )
biochirp
Posted - 1 month ago
$PRQR come on $ALNY 1.5B all stock deal gets it done
